Decreased BRCA1 mRNA expression in a breast cancer cell line led to a greater sensitivity to cisplatin and etoposide and to a greater resistance to the microtubule-interfering agents paclitaxel and vincristine (Lafarge et al, 2001). Here, BRCA1 is linked to breast cancer.